[ABSTRAK
Latar belakangDiabetes tipe 2 ditandai dengan resistensi dan defisiensi insulin, selain itu seiring denganpenuaan kejadian resistensi insulin juga semakin meningkat. Pada studi-studi klinis, resistensiinsulin dan diabetes tipe 2 terbukti meningkatkan kejadian sindrom frailty pada usila. Obatantidiabetik oral metformin telah dikaitkan dengan penghambatan proses penuaan. Namundemikian, sampai saat ini belum ada data yang menunjukkan manfaat terapi metformin terhadapkejadian sindrom frailty. Penelitian ini bertujuan untuk melihat apakah ada efek protektifmetformin terhadap sindrom frailty.MetodologiStudi ini dilakukan secara kasus kontrol pada subyek berusia ≥60 tahun yang berobat dipoliklinik Geriatri dan Diabetes FKUI-RSCM, bulan Maret-Juni 2013. Diagnosis frailtydilakukan dengan menggunakan indeks frailty-40 item (FI-40). Analisis statistik dilakukandengan metode chi-square untuk analisis bivariat dan regresi logistik untuk analisis multivariat,semua data disertai dengan interval kepercayaan 95%.HasilSindrom frailty didapatkan pada 25% (n=59) subyek penelitian, sedangkan pre-frail pada 72%(n=170) subyek dan sisanya fit. Metformin ditemukan mempunyai hubungan dengan sindromfrailty pada usila dengan diabetes mellitus tipe 2, yang tetap bermakna setelah dilakukan analisismultivariat (adjusted OR 0,043; IK 95% 0,019 – 0,099; p<0,001).

---

ABSTRACT
BackgroundType 2 diabetes (T2DM) was characterised with insulin resistance and deficiency, furthermorewith advancing age the was also an increase in insulin resistance. Clinical studies has proventhat insulin resistance and T2DM increase the incidence of frailty syndrome in the elderly. Oralantidiabetics metformin was associated with the inhibition of aging process. Eventhough, therewas no data that showed the relationship of metformin therapy to frailty syndrome. This studyaimed to explore the possibility of metformin protective effect on frailty syndrome.MethodologyThis was a case control study conducted in subjects ≥60 years old who visited the Geriatrics andDiabetes outpatient clinic of Cipto Mangunkusumo National Referral Hospital between Marchand June 2013. Diagnosis of frailty was established using the FI-40 item criteria. Statisticalanalysis was done with chi-square method for bivariate and logistic regression method inmultivariate analysis, all data was accompanied with 95% confidence interval.ResultsFrailty syndrome was found in 25% of subjects (n=59), with median age of 72 years old (SD6.27) and median of FI-40 item score was 0.18 (SD 0.085). Metformin was found to have asignificant relationship with frailty syndrome in the elderly diabetics, which retained significantvalue after multivariate analysis (adjusted OR 0.043; 95% CI 0.019-0.099; p<0.001).ConclusionMetformin was shown to have protective effect against frailty syndrome in elderly diabetics.;BackgroundType 2 diabetes (T2DM) was characterised with insulin resistance and deficiency, furthermorewith advancing age the was also an increase in insulin resistance. Clinical studies has proventhat insulin resistance and T2DM increase the incidence of frailty syndrome in the elderly. Oralantidiabetics metformin was associated with the inhibition of aging process. Eventhough, therewas no data that showed the relationship of metformin therapy to frailty syndrome. This studyaimed to explore the possibility of metformin protective effect on frailty syndrome.MethodologyThis was a case control study conducted in subjects ≥60 years old who visited the Geriatrics andDiabetes outpatient clinic of Cipto Mangunkusumo National Referral Hospital between Marchand June 2013. Diagnosis of frailty was established using the FI-40 item criteria. Statisticalanalysis was done with chi-square method for bivariate and logistic regression method inmultivariate analysis, all data was accompanied with 95% confidence interval.ResultsFrailty syndrome was found in 25% of subjects (n=59), with median age of 72 years old (SD6.27) and median of FI-40 item score was 0.18 (SD 0.085). Metformin was found to have asignificant relationship with frailty syndrome in the elderly diabetics, which retained significantvalue after multivariate analysis (adjusted OR 0.043; 95% CI 0.019-0.099; p<0.001).ConclusionMetformin was shown to have protective effect against frailty syndrome in elderly diabetics., BackgroundType 2 diabetes (T2DM) was characterised with insulin resistance and deficiency, furthermorewith advancing age the was also an increase in insulin resistance. Clinical studies has proventhat insulin resistance and T2DM increase the incidence of frailty syndrome in the elderly. Oralantidiabetics metformin was associated with the inhibition of aging process. Eventhough, therewas no data that showed the relationship of metformin therapy to frailty syndrome. This studyaimed to explore the possibility of metformin protective effect on frailty syndrome.MethodologyThis was a case control study conducted in subjects ≥60 years old who visited the Geriatrics andDiabetes outpatient clinic of Cipto Mangunkusumo National Referral Hospital between Marchand June 2013. Diagnosis of frailty was established using the FI-40 item criteria. Statisticalanalysis was done with chi-square method for bivariate and logistic regression method inmultivariate analysis, all data was accompanied with 95% confidence interval.ResultsFrailty syndrome was found in 25% of subjects (n=59), with median age of 72 years old (SD6.27) and median of FI-40 item score was 0.18 (SD 0.085). Metformin was found to have asignificant relationship with frailty syndrome in the elderly diabetics, which retained significantvalue after multivariate analysis (adjusted OR 0.043; 95% CI 0.019-0.099; p<0.001).ConclusionMetformin was shown to have protective effect against frailty syndrome in elderly diabetics.]